BioCorRx Inc. is a healthcare company specializing in addiction treatment solutions and pharmaceutical development of long-acting naltrexone implants.

# Company Summary: BioCorRx Inc.

## Business Overview
- **Industry**: Healthcare, specializing in addiction treatment and medication development
- **Core Focus Areas**:
  - Development and provision of addiction treatment solutions for substance use disorders, including opioid and alcohol dependence
  - Drug development through pharmaceutical subsidiaries aiming for FDA approval of implantable medication pellets
  - Provision of recovery and weight management programs to healthcare providers

## Key Products and Programs
- **BioCorRx® Recovery Program**:
  - A non-addictive, medication-assisted treatment (MAT) program for substance abuse
  - Includes proprietary Cognitive Behavioral Therapy (CBT) modules
  - Peer support via a mobile app
  - Prescribed medications, with treatment decisions made by independent physicians
- **UnCraveRx® Weight Loss Program**:
  - Medication-assisted weight loss program
  - Includes access to wellness support specialists (nutritionists, fitness experts, behavioral specialists)
  - Available to healthcare providers for patient use

## Pharmaceutical Development
- **Product Candidates**:
  - **BICX102**:
    - An implantable long-acting naltrexone pellet for opioid dependence and alcohol use disorders
    - Developed under NIH award, with FDA pre-IND meetings completed
  - **BICX104**:
    - A biodegradable, sustained-release naltrexone implant for opioid use disorder
    - Undergoing clinical development supported by NIH grants
    - Achieved Phase I safety and safety tolerance in healthy volunteers
- **Progress**:
  - Managed via collaborations with NIH and federal agencies
  - Funded through multiple NIH grants totaling over $11 million as of March 2024
  - Ongoing research for treating methamphetamine use disorder (MUD) with grants for over $11 million

## Customer Base and Partnerships
- **Licensed Providers**:
  - About 12 licensed providers offer the BioCorRx® Recovery Program
  - About 8 providers offer the UnCraveRx® Weight Loss Program
- **Licensing & Distribution**:
  - Several third-party agreements to establish addiction rehabilitation centers and programs
- **Research & Trials**:
  - Partnered with Charles River Laboratories for preclinical studies
  - Conducted Phase I human safety studies
  - Clinical trials in partnership with Orange County Research Center and FDA pathways pursued

## Revenue and Financials (2024)
- **Total Revenue**:
  - $7,665 (significantly decreased from prior year)
- **Expenses**:
  - Operating expenses: $5,130,170
- **Net Income/Loss**:
  - Net loss attributable to BioCorRx: **$5,106,124**
- **Grant Income**:
  - $1,473,276 (from NIH grants supporting research)
- **Other Financials**:
  - Primarily financed through equity offerings, debt, and government grants
  - Total assets as of December 31, 2024: **$385,941**
  - Cash on hand as of December 31, 2024: **$88,033**
- **Employees**:
  - Specific employee count not provided

## Additional Details
- The company operates in a highly regulated environment, pursuing FDA approval for its pharmaceutical products
- Development pipeline relies heavily on government grants and collaborations
- The company has a history of operating losses, with significant ongoing research and development expenses
- No current significant revenue from product sales; primarily funded through grants and financings

BioCorRx Inc. develops innovative treatment programs for substance use disorders, focusing on medication-assisted solutions.

# BioCorRx Inc. Overview

BioCorRx Inc. is a company dedicated to developing and providing innovative treatment programs for substance use disorders and related issues. The company operates through its subsidiaries, particularly BioCorRx Pharmaceuticals Inc., which is focused on the research and development of sustained release naltrexone products. Below are the key highlights of the company's operations, offerings, and financial status:

## Business Operations

### Treatment Programs
1. **BioCorRx® Recovery Program**
   - A non-addictive, medication-assisted treatment (MAT) program designed to help individuals recover from substance abuse.
   - Incorporates proprietary Cognitive Behavioral Therapy (CBT) modules along with peer support, complemented by medications prescribed by independent healthcare professionals.

2. **UnCraveRx® Weight Loss Management Program**
   - A medication-assisted program aimed at weight loss, providing access to concierge on-demand wellness specialists (nutritionists, fitness experts, behavioral specialists).
   - Full program launched on October 1, 2019.

### Product Development
- BioCorRx Pharmaceuticals is developing **BICX104**, an implantable naltrexone pellet aimed at treating opioid use disorders (OUD) and alcohol use disorders.
- The company is also exploring the treatment of methamphetamine use disorder (MUD) with BICX104.
- The U.S. FDA has cleared the Investigational New Drug Application (IND) for BICX104.

### Distribution and Licensing
- BioCorRx has established several license and distribution agreements with unrelated third parties for the creation of addiction rehabilitation programs.
- As of March 29, 2024, approximately **14 licensed providers** have adopted the BioCorRx Recovery Program, and **11 providers** have adopted the UnCraveRx program.

## Financial Performance

### Key Financial Metrics (as of December 31, 2023)
- **Revenue**: $89,160, compared to $213,841 in 2022, reflecting a **58% decrease** in revenue.
- **Net Loss**: $3,766,913, a slight decrease from $4,369,413 in 2022.
- **Operating Expenses**: Total of $3,876,956, down from $4,911,836 in the previous year.
- **Grant Income**: $932,996, down from $1,789,496 in 2022, indicating reduced funding or grants received.

### Cash and Funding
- **Cash Position**: As of December 31, 2023, the company had Cash of **$65,222**.
- The company has historically relied on private placements of securities for operational funding and expects to need additional capital to continue operations.

## Employees
- As of the latest reports, BioCorRx's operations are supported by a small team, with ongoing plans to hire additional staff to enhance internal controls and operational capabilities.

## Market Overview
- The services provided by BioCorRx target a broad market of individuals suffering from substance use disorders, with a significant focus on opioid and alcohol addiction treatment due to rising national concerns over these issues.

## Conclusion
BioCorRx Inc. is positioned as an emerging player in the addiction treatment space, with a line of innovative programs and products aimed at improving outcomes for patients dealing with substance use disorders. However, the company's financial metrics highlight challenges, particularly in revenue generation, which poses risks to its ongoing operations and development efforts.

BioCorRx Inc.

10-K / March 31, 2025

10-K / April 1, 2024

10-K / March 31, 2025

Company Summary: BioCorRx Inc.

Business Overview

Key Products and Programs

Pharmaceutical Development

Customer Base and Partnerships

Revenue and Financials (2024)

Additional Details